港股创新药精选ETF(520690)今日正式上市交易，其标的指数年内涨幅101.58%

格隆汇2025-08-01

港股创新药精选ETF(520690)今日正式上市交易，其紧密跟踪恒生港股通创新药精选指数，聚焦创新药龙头、精选高流动重研发标的，权重股包括百济神州、信达生物、药明生物、康方生物、石药集团、中国生物制药、三生制药、翰森制药、再鼎医药、药明康德等龙头公司。在政策支持、技术突破、资金回流共振，创新药板块或正迎来系统性重估。Wind数据显示，截至7月31日，港股通创新药精选指数年内涨幅101.58%。 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2556857137?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-01 09:18","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2556857137","market":"sh","top_or_hot":-1,"title":"港股创新药精选ETF(520690)今日正式上市交易，其标的指数年内涨幅101.58%","media":"格隆汇","content":"<div>\n<p>港股创新药精选ETF(520690)今日正式上市交易，其紧密跟踪恒生港股通创新药精选指数，聚焦创新药龙头、精选高流动重研发标的，权重股包括百济神州、信达生物、药明生物、康方生物、石药集团、中国生物制药、三生制药、翰森制药、再鼎医药、药明康德等龙头公司。\n在政策支持、技术突破、资金回流共振，创新药板块或正迎来系统性重估。Wind数据显示，截至7月31日，港股通创新药精选指数年内涨幅101.58%。\n...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股创新药精选ETF(520690)今日正式上市交易，其标的指数年内涨幅101.58%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股创新药精选ETF(520690)今日正式上市交易，其标的指数年内涨幅101.58%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-01 09:18 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/rss/live/live.xml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>港股创新药精选ETF(520690)今日正式上市交易，其紧密跟踪恒生港股通创新药精选指数，聚焦创新药龙头、精选高流动重研发标的，权重股包括百济神州、信达生物、药明生物、康方生物、石药集团、中国生物制药、三生制药、翰森制药、再鼎医药、药明康德等龙头公司。\n在政策支持、技术突破、资金回流共振，创新药板块或正迎来系统性重估。Wind数据显示，截至7月31日，港股通创新药精选指数年内涨幅101.58%。\n...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0516422952.EUR","symbol_name":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2556857137","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556857137","pubTimestamp":1754011133,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"港股创新药精选ETF(520690)今日正式上市交易，其紧密跟踪恒生港股通创新药精选指数，聚焦创新药龙头、精选高流动重研发标的，权重股包括百济神州、信达生物、药明生物、康方生物、石药集团、中国生物制药","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","600056":"中国医药","603259":"药明康德","688235":"百济神州","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","01093":"石药集团","ONC":"百济神州","01530":"三生制药","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0823426308.USD":"法巴中国股票基金","06978":"永泰生物-B","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1593":"医美概念股","01801":"信达生物","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","BK1515":"抗疫概念","LU0359201612.USD":"贝莱德中国基金A2","09926":"康方生物","BK4139":"生物科技","03692":"翰森制药","HSTECH":"恒生科技指数","FDN":"First Trust Dow Jones Internet I","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","ZLAB":"再鼎医药","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","02359":"药明康德","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","02269":"药明生物","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","09688":"再鼎医药","HSCEI":"国企指数","YANG":"三倍做空富时中国ETF-Direxion","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","01177":"中国生物制药","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1589":"北水核心资产","BK4588":"碎股","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","06160":"百济神州","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","07226":"南方两倍做多恒科","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","BK1576":"医药外包概念","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC"},"translate_title":"Hong Kong Stock Innovative Drug Select ETF (520690) was officially listed for trading today, and its underlying index rose by 101.58% during the year","themeId":"fd6a6c70759e8ef3649b21dc64b4506e","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"600056":1,"603259":1,"688235":1,"06978":1,"ONC":1,"HSCEI":1,"06160":1,"ZLAB":1,"03692":1,"01177":1,"HSTECH":1,"YANG":1,"07226":1,"09926":1,"02269":1,"01801":1,"FDN":1,"02359":1,"01530":1,"09688":1,"01093":1},"content_text":"港股创新药精选ETF(520690)今日正式上市交易，其紧密跟踪恒生港股通创新药精选指数，聚焦创新药龙头、精选高流动重研发标的，权重股包括百济神州、信达生物、药明生物、康方生物、石药集团、中国生物制药、三生制药、翰森制药、再鼎医药、药明康德等龙头公司。\n在政策支持、技术突破、资金回流共振，创新药板块或正迎来系统性重估。Wind数据显示，截至7月31日，港股通创新药精选指数年内涨幅101.58%。\n业内人士认为，中国创新药产业正经历从量变到质变的战略跃迁，在人口结构变革、政策红利释放、技术突破共振的三重驱动下，行业步入高速发展的黄金周期。中国医药创新生态正经历从“跟随创新”到“引领创新”的历史性转变。\n恒生港股通创新药精选指数作为市场首个精准聚焦该领域的指数化工具，通过严谨的编制规则和动态优化机制，为投资者提供了参与这一变革的高效工具。\n在产业政策红利持续释放、企业盈利拐点逐步显现、全球竞争力不断强化的背景下，该指数有望成为分享中国医药创新红利的核心配置标的。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2556857137","isCrawlerRequest":true}